Deal-Making
Acquisition
Deal MakingAstraZeneca adds respiratory vaccine pipeline through $1.1bn Icosavax dealAstraZeneca adds respiratory vaccine pipeline through $1.1bn Icosavax deal
AstraZeneca will add a virus-like particle vaccine technology and a Phase II respiratory syncytial virus (RSV) through the planned acquisition of Icosavax.